DAFTAR PUSTAKA

Abdullah, M., Behera, A., Kaul, V., Agarwal, P., Prasad, N., Prasad, D., Bhadauria, M., Patel, H. & Sharma, H., 2024. The unusual adverse effects of antituberculosis therapy in kidney patients. *International Journal of Mycobacteriology*, 13(2), pp. 183-190. https://doi.org/10.4103/ijmy.ijmy_33_24.

Alarcon-Braga, E.A., Salazar-Valdivia, F.E., Estrada-Grossmann, J.M., et al., 2024. Pre-extensively drug-resistant and extensively drug-resistant tuberculosis in Latin America and the Caribbean: A systematic review and meta-analysis. *American Journal of Infection Control*, 52(1), pp. 34-45.

Alomar, M.J., 2014. Factors affecting the development of adverse drug reactions (Review Article). *Saudi Pharmaceutical Journal*, 22(2), pp. 83–94.

Ategyeka, P.M., Muhoozi, M., Naturinda, R., Kageni, P., Namugenyi, C., Kasolo, A., et al., 2023. Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda. *BMC Infectious Diseases*, 23(1), p. 149.

Atif, M., Ahmed, W., Nouman Iqbal, M., Ahmad, N., Ahmad, W., Malik, I., et al., 2022. Frequency and factors associated with adverse events among multi-drug-resistant tuberculosis patients in Pakistan: A retrospective study. *Frontiers in Medicine*, 8, p. 790718.

Aung, K.J.M., Van Deun, A., Declercq, E., Sarker, M.R., Das, P.K., Hossain, M.A., Rieder, H.L. & Rigouts, L., 2014. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. *The International Journal of Tuberculosis and Lung Disease*, 18(10), pp. 1180–1187. https://doi.org/10.5588/ijtld.14.0100.

Ausi, Y., Santoso, P., Sunjaya, D. & Barliana, M., 2021. Between curing and torturing: Burden of adverse reaction in drug-resistant tuberculosis therapy. *Patient Preference and Adherence*, 15, pp. 2597–2607. https://doi.org/10.2147/PPA.S333111.

Ausi, Y., Yunivita, V., Santoso, P., Sunjaya, D., Barliana, M. & Ruslami, R., 2024. A mixed-method study of medication-related burden among multi-drug-resistant tuberculosis patients in West Java, Indonesia. *ClinicoEconomics and Outcomes Research: CEOR*, 16, pp. 707–719. https://doi.org/10.2147/CEOR.S473768.

Azeez, A., Ndege, J. & Mutambayi, R., 2018. Associated factors with unsuccessful tuberculosis treatment outcomes among tuberculosis/HIV coinfected patients with drug-resistant tuberculosis. *International Journal of Mycobacteriology*, 7(4), pp. 347.

Baghaei, P., Marjani, M., Javanmard, P., Tabarsi, P. & Masjedi, M.R., 2013. Diabetes mellitus and tuberculosis: facts and controversies. *Journal of Diabetes & Metabolic Disorders*, 12(1), p. 58.

Datta, D., Rao, I., Prabhu, A., Nagaraju, S., Thunga, G., Magazine, R., Nagri, S., Shetty, R., Khader, N., Rangaswamy, D., Shenoy, S., Bhojaraja, M. and Kamath, A., 2024. Effect of chronic kidney disease on adverse drug reactions to anti-tubercular treatment: a retrospective cohort study. *Renal Failure*, 46. https://doi.org/10.1080/0886022X.2024.2392883.

Di Gennaro, F., Marotta, C., Antunes, M. and Pizzol, D., 2019. Diabetes in active tuberculosis in low-income countries: to test or to take care? *The Lancet Global Health*.

Elkhatib, W., et al. 2015. *Pharmacokinetics of Anti-Tuberculosis Drugs in Patients with Malnutrition: Implications for Dosing*. Tuberculosis Research Journal, 12(5), 1142-1150.

Farhat, M., Cox, H., Ghanem, M., et al., 2023. Drug-resistant tuberculosis: A persistent global health concern. *Nature Reviews Microbiology*, 21(5), pp. 255-267.

Gawande, R., et al. (2019). *Workplace and Its Impact on the Adherence to Tuberculosis Treatment: A Review*. Tuberculosis Research Journal, 8(2), 45-58.

Gupta, A., Kumar, V., Natarajan, S. and Singla, R., 2020. Adverse drug reactions & drug interactions in MDR-TB patients. *Indian Journal of Tuberculosis*, 67(4), pp.S69–78. https://doi.org/10.1016/j.ijtb.2020.09.027.

Hidayat, M., & Wulandari, S. (2018). *Hubungan Status Gizi dengan Kejadian Efek Samping Pengobatan Tuberkulosis Multi Drug-Resistant (MDR) di RSUP Dr. Sardjito Yogyakarta*.

Huangfu, P., Ugarte-Gil, C., Golub, J., Pearson, F. and Critchley, J., 2019. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease*, 23(7), pp.783–796. https://doi.org/10.5588/ijtld.18.0433.

Isaakidis, P., Casas, E., Das, M., Tseretopoulou, X., Ntzani, E. and Ford, N., 2015. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. *The International Journal of Tuberculosis and Lung Disease*.

Isaakidis, P., Varghese, B., Mansoor, H., Cox, H., Ladomirska, J., Saranchuk, P., Da Silva, E., Khan, S., Paryani, R., Udwadia, Z., Migliori, G., Sotgiu, G. and Reid, T., 2012. Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. *PLoS ONE*, 7. https://doi.org/10.1371/journal.pone.0040781.

Iqbal, M. and Puspaningtyas, D.E., 2019. Penilaian Status Gizi ABCD. Cetakan ke. Jakarta: Salemba Medika.

Kamal, K., et al. (2017). *The Role of Occupational Stress on Health Outcomes: A Systematic Review*. International Journal of Occupational Medicine, 18(3), 255-268.

Kang, Y., Kim, S., Jo, K., Kim, H., Park, S., Kim, T., Kim, E., Lee, K., Lee, S., Park, J., Koh, W., Kim, D., & Shim, T. (2013). Impact of Diabetes on Treatment Outcomes and Long-Term Survival in Multidrug-Resistant Tuberculosis. *Respiration*, 86, 472 - 478. https://doi.org/10.1159/000348374.

Kementerian Kesehatan RI, 2023. *Profil Kesehatan Indonesia 2023*. Jakarta: Kemenkes RI.

Kementerian Kesehatan RI, 2023. *Laporan Tahunan Tuberkulosis*.

Kementerian Kesehatan Republik Indonesia, 2021. *Manajemen Terpadu Pengendalian TB Resisten Obat (MTPTRO)*. Available at: https://tbindonesia.or.id/pustaka-tbc/informasi/teknis/tb-mdr/.

Khan, F.U., Khan, A., Khan, F.U., Hayat, K., Rehman, A., Chang, J. et al., 2022. Assessment of adverse drug events, their risk factors, and management among patients treated for multidrug-resistant TB: A prospective cohort study from Pakistan. *Frontiers in Pharmacology*.

Lazarus, G., Tjoa, K., Iskandar, A., Louisa, M., Sagwa, E., Padayatchi, N. and Soetikno, V., 2021. The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis. *PLoS ONE*, 16. https://doi.org/10.1371/journal.pone.0248017.

Mahardani, P., Wati, D., Siloam, A., Savitri, N. and Manggala, A., 2021. Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies. *Oman Medical Journal*, 37, pp.e337. Available at: https://doi.org/10.5001/omj.2021.64

Meghna, K., Rajeshwari, R. and Kumar, P., 2021. Adherence and adverse drug reactions in MDR-TB treatment: The role of education. *Indian Journal of Respiratory Medicine*, 29(4), pp.215–220.

Menteri Kesehatan Republik Indonesia, 2019. *Keputusan Menteri Kesehatan Republik Indonesia No 755 Tahun 2019*.

Mikiashvili, L., Kempker, R., Chakhaia, T., Bablishvili, N., Avaliani, Z., Lomtadze, N., Schechter, M. and Kipiani, M., 2023. Impact of Prior TB Treatment with New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for MDR/RR-TB. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. Available at: https://doi.org/10.1093/cid/ciad694.

Muñoz-Torrico, M., Caminero-Luna, J., Migliori, G., D'Ambrosio, L., Carrillo-Alduenda, J., Villareal-Velarde, H., Torres-Cruz, A., Flores-Vergara, H., Martínez-Mendoza, D., García-Sancho, C., Centis, R., Salazar-Lezama, M. and Pérez-Padilla, R., 2017. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis. *Archivos de Bronconeumología*. Available at: https://doi.org/10.1016/j.arbres.2016.10.021.

Nadarajah, K., Khan, A., Ali, I., Aftab, R. and Shaik, I., 2019. Gender Differences and Treatment Outcome among Drug Induced Hepatotoxicity Tuberculosis Patients. *Open Medicine Journal*. Available at: https://doi.org/10.2174/1874220301906010026.

Nilamsari, W.P., Rizqi, M.F., Regina, N.O., Wulaningrum, P.A. and Fatmawati, U., 2021. Adverse Drug Reaction and Its Management in Tuberculosis Patients with Multidrug Resistance: A Retrospective Study. *Journal of Basic and Clinical Physiology and Pharmacology*, 32(4), pp.783–787.

Ninburg, M., et al. 2017. *Impact of Malnutrition on Tuberculosis Treatment Outcomes*. International Journal of Tuberculosis and Lung Disease, 21(2), 216-222.

Podewils, L., Holtz, T., Riekstiņa, V., Skripconoka, V., Zarovska, E., Kirvelaite, G., Kreigere, E. and Leimane, V., 2010. Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients. *Epidemiology*

and Infection, 139, pp.113–120. Available at: https://doi.org/10.1017/S0950268810000907.

Pradhan, A., Pradhan, S., & Parajuli, A. (2018). Gender differences in adverse drug reactions among patients undergoing tuberculosis treatment: A cross-sectional study. *Journal of Clinical Pharmacology*, 58(4), 483–489.

Prihantoro, P., Kurniawati, E., & Soeroso, M. 2020. Risk factors influencing treatment adherence among tuberculosis patients in Jakarta. *International Journal of Tuberculosis and Lung Disease*, 24(1), 48-53.

Putri, L.W.K., 2018. Kejadian Multidrug Resistant Tuberculosis (MDR TB) Di Kabupaten Banyuwangi Tahun 2017. Skripsi. Fakultas Kesehatan Masyarakat, Universitas Jember, Jember.

Rafique, S., Ahmad, N., Khan, S., Khan, A., Atif, M., Wahid, A., Khan, A. and Waheed, H., 2024. Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug-resistant tuberculosis in Balochistan, Pakistan. *Journal of Pharmaceutical Policy and Practice*, 17. Available at: https://doi.org/10.1080/20523211.2024.2332878.

Reis-Santos, B., Gomes, T., Horta, B.L. and Maciel, E.L.N., 2013. The outcome of tuberculosis treatment in subjects with chronic kidney disease in Brazil: a multinomial analysis. *Jornal Brasileiro de Pneumologia*, 39(5), pp.585–594.

Said, A., Lyakurwa, D., Sasi, P., Mvungi, H., Mpagama, S. and Mugusi, S., 2023. Prevalence and Predictors of Adverse Events Among Patients Receiving Multi-Drug Resistant Tuberculosis Treatment at Kibong'oto Infectious Disease Hospital, Tanzania: A Retrospective Study. *Tanzania Journal of Health Research*, 24(2), pp.107–120.

Sarwani, D., Nurlela, S. and Zahrotul, I., 2012. Faktor risiko multidrug resistant tuberculosis (MDR-TB). *Jurnal Kesehatan Masyarakat*, 8(1), pp.60–66.

Shi, L., Gao, J., Gao, M., Deng, P., Chen, S., He, M., Feng, W., Yang, X., Huang, Y., He, F., Hu, Y., Lei, L., Li, X., Du, J., Hu, X., Liu, Z., Tang, P., Han, J., Wang, H., Han, Y., Shu, W., Sun, Y., Pei, Y. and Liu, Y., 2021. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. *Infectious Diseases and Therapy*, 10, pp.457–470. Available at: https://doi.org/10.1007/s40121-021-00396-9.

Sinha, P., Ponnuraja, C., Gupte, N., Babu, P., Cox, S., Sarkar, S., Mave, V., Paradkar, M., Cintron, C., Govindarajan, S., Kinikar, A., Priya, N., Gaikwad, S., Thangakunam, B., Devarajan, A., Dhanasekaran, M., Tornheim, J., Gupta, A., Salgame, P., Christopher, D., Kornfeld, H., Viswanathan, V., Ellner, J., Horsburgh, C., Gupte, A., Padmapriyadarsini, C. and Hochberg, N., 2022. Impact of Undernutrition on Tuberculosis Treatment Outcomes in India: A Multicenter Prospective Cohort Analysis. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. Available at: https://doi.org/10.2139/ssrn.4077891.

Smith, J., Gandhi, N., Shah, N., Mlisana, K., Moodley, P., Johnson, B., Allana, S., Campbell, A., Nelson, K., Master, I. and Brust, J., 2020. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. Available at: https://doi.org/10.1097/QAI.0000000000002190.

Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M.J., Rao, M., & Ntoumi, F. (2019). Tuberculosis and host-directed therapies: A new era for an old disease. *The Lancet Infectious Diseases*, 19(4), 265–283.

Velayutham, B.R.V., Nair, D., Chandrasekaran, V., Raman, B., Sekar, G., Watson, B., et al., 2014. Profile and response to anti-tuberculosis treatment among elderly tuberculosis patients treated under the TB Control programme in South India.

Verma, M., et al., 2016. Drug-Drug Interactions in TB-Diabetes Comorbidity: A Double Trouble for the Management of Both Diseases. *Frontiers in Pharmacology.*

Widiastuti, E.N., et al., 2017. Determinan Kejadian Multi Drug Resistant Tuberculosis di Rumah Sakit Dr. Sardjito Yogyakarta. *Journal of Community Medicine and Public Health,* 33(7), pp. 325–330.

Wirdani, 2000. Hubungan Keberadaan PMO dengan Keteraturan Minum Obat Fase Intensif Penderita TB Paru di Puskesmas Kabupaten Pandeglang Tahun 2000. *Tesis.* Fakultas Kesehatan Masyarakat, Universitas Indonesia: Depok.

World Health Organization (WHO), 2023. *Global Tuberculosis Report 2023.* Geneva: WHO Press.

World Health Organization (WHO), 2022. *Global Tuberculosis Report 2022.* Geneva: WHO Press.

World Health Organization (WHO), 2021. *Global tuberculosis report 2021*. Geneva: WHO Press.

World Health Organization (WHO), 2022. *Consolidated Guidelines on Tuberculosis: Treatment of Drug-Resistant Tuberculosis, 2022 Update.* Geneva: WHO Press.